HROW Company Profile and Key Details

Q: Who are the executives of HROW?

Mr. Mark L. Baum J.D.Chief Executive Officer & ChairmanMr. Andrew LivingstonChief Innovation OfficerMr. Andrew R. Boll C.F.A., C.M.A., CFA, CMAChief Financial Officer & Corporation Sec.Dr. Dennis E Saadeh Pharm.D.Chief Scientific OfficerMr. David MoufarrègeVice President of TechnologyJamie WebbDirector of Communications & Investor RelationsDr. Larry M. Dillaha M.D.Chief Medical OfficerDr. Robert J. Kammer D.D.S.Special AdvisorMr. John P. Saharek MBAChief Commercial OfficerMs. Kim BarrattChief Talent OfficerMs. Jamie WebbDirector of Communications & Investor RelationsDr. Mark A. Mannebach Ph.D., R.Ph.Head of Regulatory Affairs & Pharmacovigilance

NASDAQ : HROW

Harrow Health

$42.41

-0.46-1.07%

At Close 4:00 PM

69.07

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Harrow Health, Inc. (HROW) stock declined over -1.07%, trading at $42.41 on NASDAQ, down from the previous close of $42.87. The stock opened at $43.08, fluctuating between $42.30 and $44.50 in the recent session.

Stock Snapshot

42.87

Prev. Close

1.58B

Market Cap

42.295

Day Low

-111.61

P/E Ratio

-0.38

EPS (TTM)

-4.21

Cash Flow per Share

43.08

Open

37.28M

Number of Shares

44.5

Day High

73.59%

Free Float in %

1.99

Book Value

830.96K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	43.11	44.50	42.30	42.41	830.96K
Jun 18, 2026	42.63	42.98	41.25	42.87	1.07M
Jun 17, 2026	38.72	42.47	38.52	41.94	1.23M
Jun 16, 2026	39.37	39.52	38.09	38.40	374.86K
Jun 15, 2026	38.14	39.76	37.86	38.93	608.73K
Jun 12, 2026	38.20	39.91	37.46	37.64	740.6K
Jun 11, 2026	35.95	38.21	35.50	37.65	872.69K
Jun 10, 2026	33.52	37.64	33.09	35.90	1.28M
Jun 09, 2026	33.60	34.43	33.23	33.46	888.45K
Jun 08, 2026	33.23	33.80	32.78	33.10	761.65K
Jun 05, 2026	34.59	34.90	33.10	33.19	647.65K
Jun 04, 2026	33.57	35.15	33.56	34.69	546.4K
Jun 03, 2026	33.03	34.10	32.45	33.32	792.64K
Jun 01, 2026	35.15	35.53	34.06	34.11	521.14K
May 29, 2026	35.20	35.87	34.45	35.21	953.96K
May 28, 2026	33.85	36.00	33.66	35.39	583.78K
May 27, 2026	34.52	34.96	33.54	34.43	766.44K
May 26, 2026	33.11	34.25	32.70	34.17	992.42K
May 22, 2026	33.39	33.39	32.19	33.00	681.74K
May 21, 2026	30.54	32.98	30.02	32.96	1.54M

Contact Details

Nashville, TN 37205

United States

https://www.harrowinc.com 615 733 4730

About Company

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 LNTH

2.34+2.25%

Lantheus Holdings, Inc.$106.20 ANIP

1.09+1.37%

ANI Pharmaceuticals, Inc.$80.58 SUPN

0.1+0.23%

Supernus Pharmaceuticals, Inc.$44.48 INDV

0.02+0.05%

Indivior Pharmaceuticals Inc$38.32 COLL

-0.09-0.27%

Collegium Pharmaceutical, Inc.$33.45 PAHC

-0.78-2.45%

Phibro Animal Health Corporation$31.07 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 DCPH

0.02+0.08%

Deciphera Pharmaceuticals, Inc.$25.59 ASRT

Assertio Holdings, Inc.$23.50

Company Overview

Harrow Health, Inc. (NASDAQ:HROW) closed at $42.41 USD, losing -$0.46 (-1.07%) from the previous close of $42.87. The stock is currently mid-range between its 52-week high and low $28.54 and $54.85. With a market capitalization of about $1.58 billion, Harrow Health, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.28). Key stats such as the average daily volume over the past year has been around 754.68 thousand shares, in line with its 52-week average. Headquartered in Nashville, TN, Harrow Health, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Mark L. Baum, the company employs approximately 382 people and listed since September 28, 2007. Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 11.41%, SMA50 12.28%, SMA200 36.43%). The stock’s 14-day RSI is 68.25 (firm momentum), while the ATR of 2.52 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.57% below its high and over 158.94% above its low. Average 10-day trading volume of 822.17 thousand shares is in line with the 3-month average of 769.07 thousand, indicating normal recent market interest.

Valuation Metrics

Harrow Health, Inc. trades at a P/E ratio of -110.39, slightly below the S&P 500 average, with a price-to-sales ratio of 6.01 and a price-to-book ratio of 56.2 reflecting a rich premium to book value. The P/FCF stands at 113.12, also above market averages. Compared to sector medians, Harrow Health, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Harrow Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.28. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$0.74. The next quarter is forecast at $0.37. Next year's EPS is expected at $130.32. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 17 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $94.00 to $63.00. The high target offers 121.65% upside. The low target suggests 48.55% downside. The mean target is $69.10. This offers 62.93% upside. Harrow Health, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 72.09%. The prior quarter beat by -35.0%. Over the last six quarters, Apple has recorded several small beats. These include 127.27% in March 27, 2025.

Shareholding & Insider Activity

Harrow Health, Inc. has 37.00 million shares outstanding. The public float is 27.23 million shares, elevated short interest at 16.41% of float. This equals 4.82 million shares. The short ratio is 7.74 days. Institutional investors hold 68.13% of the float. Insiders own 15.72%. BAUM MARK L holds 2.14 million shares, Longboard Capital Advisors, LLC has 1.42 million shares and Kammer Robert J has 797.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 30.57 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Harrow Health generated $130.19M in revenue, or $3.99 per share. Gross margin was 69.55%, operating margin 0.45%, and net profit margin -18.75%. Returns are negative, with ROA at -7.83% and ROE at -34.70%.
On valuation metrics, Harrow Health trades at a P/E of -110.39, P/S of 6.01 and P/B of 56.20. The current ratio is 2.48 and quick ratio is 2.30. Operationally, the company’s inventory turnover is 4.22 and cash conversion cycle is 87.04 days. Debt-to-equity is 10.47, supported by a cash flow-to-debt ratio of 0.05.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Harrow Health posted revenue of $130.19M, down slightly from $88.60M in the prior quarter. Gross profit was $90.55M (margin 69.55%). Operating income was $580.00K (margin 0.4%). Net income was- $24.41M (EPS - $0.75).
The company ended the quarter with $82.77M in cash and short-term investments, a total debt of $190.50M, and net debt of $116.42M. Total assets were $311.76M, with equity of $70.00M. Financials further reflected stability, with operating cash flow of $3.84M, free cash flow of - $148.71M, and capital expenditures of - $152.55M.

Price Forecast & Outlook

Our AI price prediction model suggests that Harrow Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.44%, with price expected at $45.14 by July 06, 2026, within a range of $42.03 to $48.46 3-Month Outlook: Projected fall of -7.88%, reaching $39.07 by September 18, 2026, with a range of $35.49 to $41.59. 1-Year Outlook: Projected gain of 16.81%, with price at $49.54 by June 22, 2027, within a range of $46.37 to $53.04.

Key Takeaways

Harrow Health, Inc. (NASDAQ:HROW) shares are flat -2.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Harrow Health, Inc. trading at a premium to the broader market with a P/E of -110.39. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $57.71, suggesting 36.08% upside. Our AI forecast model points to short-term strength (6.44% over two weeks), a medium-term fall (-7.88% over three months), and a longer-term gain (16.81% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Harrow Health, Inc. (HROW) stock price?

Harrow Health, Inc. (NASDAQ: HROW) stock price is $42.41 in the last trading session. During the trading session, HROW stock reached the peak price of $44.50 while $42.30 was the lowest point it dropped to. The percentage change in HROW stock occurred in the recent session was -1.07% while the dollar amount for the price change in HROW stock was - $0.46.

HROW's industry and sector of operation?

The NASDAQ listed HROW is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Harrow Health, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HROW?

Mr. Mark L. Baum J.D.
Chief Executive Officer & Chairman
Mr. Andrew Livingston
Chief Innovation Officer
Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA
Chief Financial Officer & Corporation Sec.
Dr. Dennis E Saadeh Pharm.D.
Chief Scientific Officer
Mr. David Moufarrège
Vice President of Technology
Jamie Webb
Director of Communications & Investor Relations
Dr. Larry M. Dillaha M.D.
Chief Medical Officer
Dr. Robert J. Kammer D.D.S.
Special Advisor
Mr. John P. Saharek MBA
Chief Commercial Officer
Ms. Kim Barratt
Chief Talent Officer
Ms. Jamie Webb
Director of Communications & Investor Relations
Dr. Mark A. Mannebach Ph.D., R.Ph.
Head of Regulatory Affairs & Pharmacovigilance

How HROW did perform over past 52-week?

HROW's closing price is 48.6% higher than its 52-week low of $28.54 where as its distance from 52-week high of $54.85 is -22.68%.

How many employees does HROW have?

Number of HROW employees currently stands at 382.

Link for HROW official website?

Official Website of HROW is: https://www.harrowinc.com

How do I contact HROW?

HROW could be contacted at phone 615 733 4730 and can also be accessed through its website. HROW operates from 102 Woodmont Boulevard, Nashville, TN 37205, United States.

How many shares of HROW are traded daily?

HROW stock volume for the day was 830.96K shares. The average number of HROW shares traded daily for last 3 months was 754.68K.

What is the market cap of HROW currently?

The market value of HROW currently stands at $1.58B with its latest stock price at $42.41 and 37.28M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	382
Beta	0.28
Sales or Revenue	$130.19M
5Y Sales Change%	1.297%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

HROW Company Profile and Key Details

Harrow Health

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook